全文获取类型
收费全文 | 10635篇 |
免费 | 522篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 179篇 |
妇产科学 | 225篇 |
基础医学 | 1228篇 |
口腔科学 | 282篇 |
临床医学 | 807篇 |
内科学 | 2856篇 |
皮肤病学 | 161篇 |
神经病学 | 1167篇 |
特种医学 | 318篇 |
外科学 | 1376篇 |
综合类 | 26篇 |
一般理论 | 3篇 |
预防医学 | 477篇 |
眼科学 | 223篇 |
药学 | 736篇 |
中国医学 | 14篇 |
肿瘤学 | 1026篇 |
出版年
2024年 | 9篇 |
2023年 | 64篇 |
2022年 | 150篇 |
2021年 | 271篇 |
2020年 | 169篇 |
2019年 | 216篇 |
2018年 | 243篇 |
2017年 | 222篇 |
2016年 | 245篇 |
2015年 | 275篇 |
2014年 | 361篇 |
2013年 | 550篇 |
2012年 | 783篇 |
2011年 | 807篇 |
2010年 | 430篇 |
2009年 | 416篇 |
2008年 | 725篇 |
2007年 | 782篇 |
2006年 | 760篇 |
2005年 | 721篇 |
2004年 | 708篇 |
2003年 | 631篇 |
2002年 | 571篇 |
2001年 | 82篇 |
2000年 | 74篇 |
1999年 | 64篇 |
1998年 | 113篇 |
1997年 | 77篇 |
1996年 | 80篇 |
1995年 | 83篇 |
1994年 | 74篇 |
1993年 | 65篇 |
1992年 | 52篇 |
1991年 | 38篇 |
1990年 | 39篇 |
1989年 | 32篇 |
1988年 | 21篇 |
1987年 | 21篇 |
1986年 | 21篇 |
1985年 | 22篇 |
1984年 | 19篇 |
1983年 | 18篇 |
1982年 | 17篇 |
1981年 | 24篇 |
1980年 | 11篇 |
1979年 | 7篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1974年 | 6篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Maurizio Fava Michael E Thase Charles DeBattista Karl Doghramji Sanjay Arora Rod J Hughes 《Annals of clinical psychiatry》2007,19(3):153-159
BACKGROUND: Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue. METHODS: This retrospective analysis pooled the data of patients (18-65 yrs) who participated in two randomized, double-blind, placebo-controlled studies of modafinil (6-week, flexible-dose study of 100-400 mg/day or 8-week, fixed-dose study of 200 mg/day) plus SSRI therapy. Patients (n=348) met criteria for several residual symptoms (Epworth Sleepiness Scale [ESS] score>or=10; 17-item Hamilton Depression Scale [HAM-D] score between 4 and 25; and Fatigue Severity Scale [FSS] score>or=4). RESULTS: Compared to placebo, modafinil augmentation rapidly (within 1 week) and significantly improved overall clinical condition (Clinical Global Impression-Improvement), wakefulness (ESS), depressive symptoms (17-item HAM-D), and fatigue (FSS) (p<.01 for all). At final visit, patients receiving modafinil augmentation experienced statistically significant improvements in overall clinical condition, wakefulness, and depressive symptoms. Modafinil was well tolerated in combination with SSRI. CONCLUSIONS: Results of this pooled analysis provide further evidence suggesting that modafinil is an effective and well-tolerated augmentation therapy for partial responders to SSRI therapy, particularly when patients continue to experience fatigue and excessive sleepiness. 相似文献
22.
Amy Farabaugh David Mischoulon Maurizio Fava Wendy Guyker Jonathan Alpert 《Annals of clinical psychiatry》2004,16(4):217-224
BACKGROUND: Research studies have focused attention on the importance of the comorbidity of personality disorders and depression. METHODS: The present review examines seven potential explanations for the overlap to clarify the nature of the relationship, if any, between depression and personality disorder diagnoses. RESULTS: There may be many explanations for the potential overlap of personality disorders (PD) and major depressive disorder (MDD). For example, the distinction between states and traits may not be as clear and definitive as suggested in the DSM-IV. In some cases, depression may influence personality pathology, and may even lead to personality disorders. In other cases, personality disorders may lead to MDD. CONCLUSION: Further research may clarify the nature of the relationship, if any, between depression and personality disorder diagnoses, as well as the relationship between comorbidity and treatment response. 相似文献
23.
Paolo Calabresi Emesto Fedele Antonio Pisani Giovanni Fontana Nicola B. Mercuri Giorgio Bernardi Maurizio Raiteri 《The European journal of neuroscience》1995,7(9):1889-1894
Using a corticostriatal slice preparation, we have recently shown that tetanic stimulation of the corticostriatal pathway produces long-term depression (LTD) of striatal excitatory synaptic transmission. In the present study we have analysed the relationship between LTD and the striatal release of different endogenous transmitters. Samples of perfusate were collected via a small cannula placed just above the surface of the striatal slice close to the recording electrode, and were analysed by HPLC. The high-frequency stimulation (100 Hz, three trains, 3 s duration, 20 s intervals) used to induce LTD caused a significant but transient increase in the release of both excitatory (aspartate and glutamate) and inhibitory (glycine and GABA) amino acid transmitters. Tetanic stimulation also produced a significant, but transient increase in the release of endogenous dopamine. We conclude that the tetanic stimulation of the corticostriatal pathway is able to induce a large but transient release of excitatory amino acids and of dopamine, whose participation in the induction of striatal LTD has been demonstrated previously. Moreover, the maintenance of this form of synaptic plasticity does not seem to require a sustained change in transmitter release. 相似文献
24.
25.
26.
Emilio Benfenati Pierluigi Farina Tina Colombo Gianluca De Bellis Mauro Valerio Capodiferro Maurizio D'Incalci 《Cancer chemotherapy and pharmacology》1989,24(6):354-358
Summary The pharmacokinetics of the anticancer agent p-(3,3-dimethyl-1-triazeno) benzoic acid (pCOOH-DMT), a drug now in phase I clinical trial in Europe, was investigated in C57 Bl female mice with M5076 reticulum-cell sarcoma that were treated i.v. with 200 mg/kg pCOOH-DMT. The drug disappeared from plasma with a terminal half-life of about 2.5 h. Plasma clearance was approximately 6 ml/min per kg. Distribution studies showed some differences in drug levels in different tissues. The highest levels were found in the tumor, liver, kidney and lung; lower levels were found in the spleen and gut, and the lowest, in the brain. The N-desmethyl derivative of pCOOH-DMT was not detectable in plasma or tissues of mice treated with the drug. Therefore, the previous evidence of low N-demethylation of pCOOH-DMT was confirmed. pCOOH-DMT glucuronide was identified by mass spectrometry and quantified by high-performance liquid chromatography (HPLC) in plasma, tissues and urine samples. pCOOH-DMT glucuronide appears to be the major urinary metabolite of pCOOH-DMT in mice. Another metabolite identified by mass spectrometry and quantified by HPLC in some tissues and urine was pCOOH-DMT glycinate.Abbreviations DTIlC
5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide
- pCOOH-DMT
p-(3,3-dimethyl-l-triazeno)benzoic acid
- pCOOH-MMT
p-(3-methyl-l-triazeno)benzoic acid
- pCONH2-DMT
p-(3,3-dimethyl-l-triazeno)carboxamide
- BSTFA
N,O-bis(trimethylsilyl)trifluoroacetamide
- TMCS
trimethylchlorosilane
- TLC
thin-layer chromatography
- FAB
fast atom bombardment
- EI
electron impact
- M5
M5076 reticulum-cell sarcoma
- t1/2
beta-half-life
- C0
concentration time 0
- AUC
area under the concentration vs time curve
- Cl
total clearance
- V
volume of distribution 相似文献
27.
28.
T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines. 相似文献
29.
Massa O Iafusco D D'Amato E Gloyn AL Hattersley AT Pasquino B Tonini G Dammacco F Zanette G Meschi F Porzio O Bottazzo G Crinó A Lorini R Cerutti F Vanelli M Barbetti F;Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology Diabetology 《Human mutation》2005,25(1):22-27
Permanent neonatal diabetes mellitus (PNDM) is a rare condition characterized by severe hyperglycemia constantly requiring insulin treatment from its onset. Complete deficiency of glucokinase (GCK) can cause PNDM; however, the genetic etiology is unknown in most PNDM patients. Recently, heterozygous activating mutations of KCNJ11, encoding Kir6.2, the pore forming subunit of the ATP-dependent potassium (K(ATP)) channel of the pancreatic beta-cell, were found in patients with PNDM. Closure of the K(ATP) channel exerts a pivotal role in insulin secretion by modifying the resting membrane potential that leads to insulin exocytosis. We screened the KCNJ11 gene in 12 Italian patients with PNDM (onset within 3 months from birth) and in six patients with non-autoimmune, insulin-requiring diabetes diagnosed during the first year of life. Five different heterozygous mutations were identified: c.149G>C (p.R50P), c.175G>A (p.V59M), c.509A>G (p.K170R), c.510G>C (p.K170N), and c.601C>T (p.R201C) in eight patients with diabetes diagnosed between day 3 and 182. Mutations at Arg50 and Lys170 residues are novel. Four patients also presented with motor and/or developmental delay as previously reported. We conclude that KCNJ11 mutations are a common cause of PNDM either in isolation or associated with developmental delay. Permanent diabetes of non autoimmune origin can present up to 6 months from birth in individuals with KCNJ11 and EIF2AK3 mutations. Therefore, we suggest that the acronym PNDM be replaced with the more comprehensive permanent diabetes mellitus of infancy (PDMI), linking it to the gene product (e.g., GCK-PDMI, KCNJ11-PDMI) to avoid confusion between patients with early-onset, autoimmune type 1 diabetes. 相似文献
30.
Giorgio Montaudo Maurizio S. Montaudo Concetto Puglisi Filippo Samperi 《Macromolecular chemistry and physics.》1995,196(2):499-511
The sequence distributions of four poly(ether-sulfone)/poly(ether-ketone) (PES/PEK) copolymer samples were determined by means of fast atom bombardment mass spectrometry (FAB-MS) and by 13C NMR spectroscopy. The controlled partial degradation of the copolymer chains to produce oligomers suitable of FAB-MS analysis was performed with sodium methoxide in dimethyl sulfoxide solution at 130°C, and the experimental conditions were optimized. The sequential arrangements of ether-sulfone/ether-ketone units present in these materials were estimated by a best-fit minimization method using the MACO4 computer program which compares the experimental FAB-MS spectral intensities with theoretical intensities. Random PES/PEK copolymer samples showed quite the same sequence arrangements as expected from monomer feed-ratios used in the syntheses. Instead, a PES/PEK copolymer sample expected to be exactly alternating (from the synthesis procedure) showed 44% of random sequences owing to the transetherification reaction which occurred in the synthesis. The results of sequential analysis obtained from 13C NMR data compare well with the data obtained by the FAB-MS analysis. 相似文献